Drug intelligence / Profile preview

Fuyanle

Development stage: Phase 3
Lead developer: Fangsheng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Fuyanle is a Traditional Chinese Medicine (TCM) product developed by Hunan Fangsheng Pharmaceutical Co., Ltd., primarily formulated as an oral capsule. It is designed for the treatment of gynecological inflammatory conditions, specifically vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV). The formulation typically utilizes a combination of herbal extracts known in TCM for their 'heat-clearing' and 'dampness-drying' properties, which provide anti-inflammatory and antimicrobial effects against common vaginal pathogens such as *Candida albicans* and various anaerobic bacteria. Clinical development in China has progressed through Phase II and Phase III trials to evaluate its efficacy and safety compared to standard antifungal or antibacterial treatments.

Brand names: Fuyanle
Other names: Fuyanle Capsule妇炎乐胶囊

Beyond the preview

Go deeper on Fuyanle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuyanle.